3-Methyl-5,6,7,8-tetrahydroquinoline-8-thiocarboxamide hydrochloride (tiquinamide) possesses potent gastric antisecretory activity in a number of animal species. It causes a marked inhibition in the volume and concentration of basal and chemically-stimulated gastric acid secretion in the conscious rat and guinea-pig, and of chemically-stimulated secretion in the anaesthetised cat, dog and monkey. Marked activity is also seen in conscious Heidenhain-pouch dogs, against secretion stimulated by betazole and gastrin tetrapeptide. In the pylorus-ligated rat preparation, the antisecretory effect of 30 mg/kg tiquinamide persists for 8-9 h. The possible mode of action of this drug, in view of its wide non-selective antisecretory profile, is discussed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Gastroprotective Effect of Hexanic Extract of Against Ethanol-Induced Gastric Lesions in a CD1 Mouse Model.
Plants (Basel)
December 2024
Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Colonia Casco de Santo Tomás, Miguel Hidalgo, Mexico City 11340, Mexico.
Peptic ulcers result from an imbalance between protective factors (e.g., prostaglandins, nitric oxide, and sulfhydryl groups) and aggressive risk factors (e.
View Article and Find Full Text PDFSurgical Therapy of Gastric Ulcer Disease.
Surg Clin North Am
February 2025
Department of General Surgery, Englewood Health Medical Center, Englewood, NJ, USA. Electronic address:
Medical advancements, including Helicobacter pylori eradication and antisecretory agents, have reduced peptic ulcer disease (PUD)-associated hospital admissions, mortality, and surgical interventions over the past 30 years. Surgery plays an important role in the treatment of life-threatening complications of PUD, such as bleeding, perforation, and gastric outlet obstruction, as well as for disease that is refractory to medical management. The article highlights the critical role of surgery in cases where medical therapy is insufficient or in the event of emergency complications arising from PUD.
View Article and Find Full Text PDFand parthenolide increase defensive agents and promote antisecretory activity supporting their gastroprotective actions in rodents.
Nat Prod Res
November 2024
Postgraduate Program in Health Sciences, Community University of Chapecó Region, Chapecó, Santa Catarina, Brazil.
Article Synopsis
- The study investigates the anti-ulcer effects of hydroalcoholic extract (HETp) and its active component parthenolide (PTL) against gastric ulcers induced by ethanol and piroxicam.
- Results showed that both HETp and PTL significantly reduced ulcer formation, with additional histological support confirming their effectiveness.
- The protective effects involve various mechanisms, including the influence of nitric oxide, adrenergic receptors, and prostaglandins, while also enhancing antioxidant levels and reducing harmful enzyme activity.
Hospitalized patients on proton pump inhibitors for stress ulcer prophylaxis have a higher risk of Clostridioides difficile infection compared with those on histamine-2 receptor antagonists.
J Hosp Infect
December 2024
Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Tainan City, Taiwan; Department of Pharmacy, National Cheng Kung University Hospital, Tainan City, Taiwan. Electronic address:
Background: Previous studies on Clostridioides difficile infection (CDI) in proton pump inhibitor (PPI) users generally enrolled a heterogeneous population and did not include a control group of histamine H2 receptor antagonists (H2RAs) users or adjust for confounding variables, such as previous antibiotics. It is uncertain whether hospitalized patients using PPIs for stress ulcer prophylaxis (SUP) are at a higher risk of CDI compared with those using H2RAs. This study aimed to compare the association between CDI and the usage of antisecretory drugs (ASDs): PPIs and H2RAs, for SUP among hospitalized patients, and the impact of the duration of their use on CDI.
View Article and Find Full Text PDFIs It Time for Noncontinuous Therapy for Gastroesophageal Reflux Disease?
Gastroenterol Hepatol (N Y)
August 2024
The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth System and Case Western Reserve University, Cleveland, Ohio.
Article Synopsis
- Gastroesophageal reflux disease (GERD) is a long-term condition where stomach contents flow back into the esophagus, potentially causing serious issues like Barrett esophagus and esophageal adenocarcinoma, with proton pump inhibitors (PPIs) being the main treatment despite needing daily use.
- Noncontinuous therapy methods for treating GERD include on-demand medication and intermittent use of antireflux drugs, which can be preferable for patients due to convenience and cost savings while addressing concerns over long-term PPI use.
- Potassium-competitive acid blockers (P-CABs) show promise for noncontinuous therapy of GERD due to their rapid effects and ease of use, although more research is needed to fully confirm their effectiveness compared to PP
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!